Vaxcyte PCVX 深 滬
已收盤 11-14 16:00:00 美东时间
48.69
+3.140
+6.89%
華盛通- 最 高49.8699
- 今 開45.62
- 成交量 220.59万股
- 最 低 45.62
- 昨 收 45.55
- 總市值 63.30亿
- 52周最高 94.76
- 市盈率 靜 --
- 換手率 1.70%
- 52周最低 27.66
- 委 比 -43.27%
- 總股本 1.30亿
- 歷史最高 121.055
- 量 比 1.78
- 振 幅 9.33%
- 歷史最低 15.51
- 每 手 1
- 風險率 24.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
BTIG Reiterates Buy on Vaxcyte, Maintains $85 Price Target
BTIG analyst Thomas Shrader reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $85 price target.
11-10 18:31
Vaxcyte GAAP EPS of -$1.56 misses by $0.25
Vaxcyte press release (PCVX): Q3 GAAP EPS of -$1.56 misses by $0.25. Ending the third quarter with $2.7 billion in cash, cash equivalents and investments. More on Vaxcyte Vaxcyte, Inc. (PCVX) Presents...
11-05 06:23
Vaxcyte Q3 EPS $(1.56) Misses $(1.30) Estimate
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate of $(1.30) by 19.82 percent. This is a 87.95 percent decrease over losses of $(0.83) per share from the
11-05 05:47
ClearBridge SMID Cap Growth Strategy
The ClearBridge SMID Cap Growth Strategy underperformed its Russell 2500 Growth Index benchmark during the third quarter, with the index gaining 10.7%. As such, the performance of SMID growth equitie...
10-13 23:15
Thermo Fisher Scientific prices $2.5B senior notes
Thermo Fisher Scientific (NYSE:TMO) priced an offering of $2.5B senior notes consiting of: $500M 4.200% senior notes due 2031 at the issue price of 99.874%; $750M 4.473% senior notes due 2032 at the...
10-01 13:28
Vaxcyte Signs 15-Year Agreement with Patheon
An update from Vaxcyte ( ($PCVX) ) is now available. On September 24, 2025, Vax...
09-30 21:24
Vaxcyte Enters Partnership With Thermo Fisher Scientific To Secure Additional U.S. Fill-Finish Commercial Manufacturing For Its Broad-Spectrum Pneumococcal Conjugate Vaccines Representing Up To $1B in Manufacturing And Service
Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced a new agreement with Thermo Fisher Scientific Inc., the world leader in serving science, to bring additional fill-finish
09-30 20:44
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
Vaxcyte has signed a deal with Thermo Fisher Scientific to expand its fill-finish commercial manufacturing capabilities in the U.S. for its broad-spectrum pneumococcal conjugate vaccines (PCVs). Thermo Fisher will provide custom manufacturing services at its Greenville, N.C., facility, supporting Vaxcyte's long-term U.S. supply strategy with up to $1 billion in capacity. The partnership aims to strengthen domestic biomanufacturing, enhance supply...
09-30 12:30
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
